Physician profile
John S Muchmore
NPI 1033163100
$2,759.70
in general payments reported to CMS, 2019-2025
30 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.97 · 2020: $168 · 2021: $60.03 · 2022: $118 · 2023: $204 · 2024: $950 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $300.98 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $238.81 | 2020-2025 | |
| Abbott Laboratories | $221.25 | 2020-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $184.59 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $170.46 | 2023-2024 | Korlym |
| Tandem Diabetes Care, INC. | $168.87 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $160.09 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $152.51 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $136.46 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $126.79 | 2024-2025 | Tymlos |
| Madrigal Pharmaceuticals | $126.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.80 | 2022-2025 | Jardiance |
| Amgen INC. | $98.37 | 2024-2025 | Tepezza, Evenity, Prolia |
| Ibsa Pharma INC. | $83.51 | 2025 | Tirosint, Flector, Licart |
| Horizon Therapeutics Plc | $81.29 | 2022-2023 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $59.89 | 2024-2025 | Strensiq |
| Antares Pharma, INC. | $36.75 | 2024 | Xyosted |
| Beta Bionics, INC. | $31.63 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $28.68 | 2025 | Yorvipath |
| Globus Medical, INC. | $27.46 | 2025 | Omnia |
| Astrazeneca Pharmaceuticals Lp | $24.83 | 2020 | |
| Acella Pharmaceuticals, LLC | $23.26 | 2025 | NP Thyroid 60 |
| Becton, Dickinson and Company | $20.21 | 2020 | |
| Averitas Pharma INC. | $20.03 | 2024 | Qutenza |
| Medtronic, INC. | $19.97 | 2024 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $19.36 | 2025 | Unithroid |
| Mannkind Corporation | $18.85 | 2025 | |
| Chiesi USA, INC. | $18.73 | 2024 | Myalept |
| Cequr Corporation | $18.21 | 2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $16.34 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Muchmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.